Not checkedNot checked for notices yet.
Review of commercially available biomarkers in the diagnosis of prostate cancer
Magdalena Ostrowska, Iwona Handzlik, Martyna Radomska and 1 more
Journal of Education, Health and Sport · 2022
doi:10.12775/jehs.2022.12.11.025 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Introduction Diagnosing prostate cancer is a complex process. Although PSA testing remains the basic laboratory study, new biomarkers and test are evolving quickly. Aim The aim of this review was to summarize available tests and markers for diagnosing prostate cancer. Materials and methods Literature search was conducted using PubMed and Cohrane databases. Results and conclusions Detailed description of ExoDx, PCA3, SelectMDx, Mi-prostate Score, SChLAP1, PSA, PHI, 4K Score tests was presented. Available test ease qualification for a prostate biopsy or observation. Patients should be qualified individually in deciding on a specific test to be performed. Urologists should be aware of each test mechanism and limitations.
Abstract licence: CC BY-NC-SA
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.